Tranexamic acid (TXA) is an antifibrinolytic medication that displaces plasminogen from the fibrin complex which should result in a more persistent clot. Given that the majority of trauma deaths are due to haemorrhage, this would seem to be a reasonable therapeutic target.


TXA has established use in the management of epistaxis and postpartum haemorrhage (1) . The CRASH-2 (2) and MATTERS (6) trials demonstrated mortality benefit in trauma patients at risk of bleeding by adding TXA to the ...


Continue reading ...